AXIM Biotechnologies (AXIM) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 30, 2014
Document and Entity Information:	'	'
Entity Registrant Name	'AXIM BIOTECHNOLOGIES, INC.	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Entity Central Index Key	'0001514946	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	33,000,000
Entity Filer Category	'Smaller Reporting Company	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Sep. 30, 2014
Current assets:	'
Cash	$949,810
Prepaid expenses	112,369
Total current assets	1,062,179
TOTAL ASSETS	1,062,179
Current liabilities:	'
Accounts payable and accrued liabilities	70,331
Due to shareholder	5,000
Convertible shareholder loan	50,000
Due to first insurance funding	95,757
Due to related party	30,000
Promissory note - related party	1,000,000
Total current liabilities	1,251,088
STOCKHOLDERS' DEFICIT	'
Preferred stock, $0.0001 par value, 5,000,000 shares authorized;1,000,000 issued and outstanding	100
Common stock, $0.0001 par value, 300,000,000 shares authorized;33,000,000 issued and outstanding	3,300
Additional paid in capital	107,841
Accumulated deficit	-300,150
TOTAL STOCKHOLDERS' DEFICIT	-188,909
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$1,062,179

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets Parentheticals (USD $)	Sep. 30, 2014
Parentheticals	'
Preferred Stock, par value	$0.00
Preferred Stock, shares authorized	5,000,000
Preferred Stock, shares issued	1,000,000
Preferred Stock, shares outstanding	1,000,000
Common Stock, par value	$0.00
Common Stock, shares authorized	300,000,000
Common Stock, shares issued	33,000,000
Common Stock, shares outstanding	33,000,000

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Sales	'	$10,833	'	$21,667
Total revenues	'	10,833	10,000	21,667
General and administrative	127,943	10,643	138,226	67,921
Impairment expenses	'	'	52,103	'
Total operating expenses	127,943	10,643	190,329	67,921
(Loss) income from operations	-127,943	190	-180,329	-46,254
Interest expense	10,804	'	10,804	'
NET (LOSS) INCOME	($138,747)	$190	($191,133)	($46,254)
Basic loss per common share	$0	$0	($0.01)	$0
Diluted loss per common share	$0	$0	($0.01)	$0
Weighted average common shares outstanding - Basic	33,000,000	33,000,000	33,000,000	33,000,000
Weighted average common shares outstanding - Diluted	33,000,000	33,000,000	33,000,000	33,000,000

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Deficit (USD $)	Common Stock Shares	Common Stock Amount	Preferred Stock Shares	Preferred Stock Amount	Additional Paid In Capital	Accumulated Deficit	Total
					USD ($)	USD ($)	USD ($)
Balance at Dec. 31, 2013	33,000,000	3,300	1,000,000	100	11,700	-109,017	-93,917
Forgiveness of debt	'	'	'	'	$96,141	'	$96,141
Net loss for the period	'	'	'	'	'	($191,133)	($191,133)
Balance at Sep. 30, 2014	33,000,000	3,300	1,000,000	100	107,841	-300,150	-188,909

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($191,133)	($46,254)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Increase in allowance for doubtful accounts	-8,000	7,500
Amortization of intangible assets	1,593	7,500
Impairment of intangible assets	52,103	'
Change in operating assets and liabilities:	'	'
Decrease in license fee receivable	11,000	9,000
Increase in accounts payable and accrued expenses	73,482	14,156
Increase in prepaid expenses	-82,369	'
Increase in due to first insurance funding	95,757	'
(Decrease) Increase in royalty fee payable	-2,750	450
Decrease in deferred revenue	'	-21,667
NET CASH USED IN OPERATING ACTIVITIES	-50,317	-29,315
CASH FLOWS FROM INVESTING ACTIVITIES	'	0
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from shareholder loan	'	11,422
Proceeds from promissory note - related party	1,000,000	'
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,000,000	11,422
NET CHANGE IN CASH	949,683	-17,893
CASH BALANCES	'	'
Beginning of year	127	19,128
End of period	949,810	1,235
CASH PAID DURING THE YEAR FOR:	'	'
Interest	0	'
Income taxes	'	0
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING TRANSACTIONS:	'	'
Gain on settlement of debt transferred to additional paid in capital	'96141	'
Prepaid insurance paid by related party	$30,000	'

ORGANISATION

ORGANISATION	9 Months Ended
	Sep. 30, 2014
ORGANISATION	'
ORGANISATION	'
	NOTE 1:  ORGANISATION
	The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc.  On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations.  The Company’s principal executive office is located at 18 East 50th Street, 5th Floor, New York, NY 10022.   On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc.  This subsidiary will be used to help facilitate the anticipated activities planned by the Company.
	In early 2014, the Company discontinued its organic waste marketable by-product business to focus on its anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids based products as well as focusing on research, development and production of pharmaceutical, nutriceutical and cosmetic products as well as procurement of genetically and nano-controlled active ingredients.

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2014
BASIS OF PRESENTATION:	'
BASIS OF PRESENTATION	'
	NOTE 2:  BASIS OF PRESENTATION:
	The unaudited interim financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) as of September 30, 2014, and for the three and nine months periods ended September 30, 2014 and 2013, have been prepared in accordance with United States generally accepted accounting principles.  In the opinion of management, such information contains all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of such periods. The results of operations of the Nine month period ended September 30, 2014 are not necessarily indicative of the results to be expected for the full year ending December 31, 2014.  The Company has adopted ASU 2014-10, and as a result, these financials will no longer incorporate the wording “Development Stage Company”. Also, the “Since inception till date” column is no longer used.
	Certain information and disclosures normally included in the notes to financial statements have been condensed or abbreviated as permitted by the rules and regulations of the Securities and Exchange Commission, although the Company believes the disclosure is adequate to make the information not misleading. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the financial information of the fiscal year ended December 31, 2013.
	On June 9, 2014, the board of directors of the Company adopted a resolution approving a certificate of amendment to the Company’s Articles of Incorporation to: (i) change the name of the Company to “AXIM Biotechnologies, Inc.;” and (ii) increase in the number of authorized shares of common stock of the Company from one hundred ninety five million (195,000,000) shares of common stock, par value $0.0001 per share, to three hundred million (300,000,000) shares of common stock, par value $0.0001 per share.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
SIGNIFICANT ACCOUNTING POLICIES:	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 3: SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation
	The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").
	Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates.
	Cash equivalents
	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
	Fair value of financial instruments
	The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	Income taxes
	The Company follows Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date.
	The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.
	Net loss per common share
	Net loss per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be antidilutive.
	Recently issued accounting standards
	In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	The Company has elected to adopt the provisions of ASU 2014-10 for the current fiscal period ending September 30, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow.
	Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future unaudited condensed consolidated financial statements

CHANGE_OF_CONTROL

CHANGE OF CONTROL	9 Months Ended
	Sep. 30, 2014
CHANGE OF CONTROL:	'
CHANGE OF CONTROL	'
	NOTE 4:  CHANGE OF CONTROL
	Two new owners purchased most of the Company common stock and all of the preferred stock on March 21, 2014.  As a part of that sale specified receivables, payables and accrued expenses were consolidated and transferred to a third party.  Because the “Debt Settlement Agreement” was a part of the stock transfer agreement the net assigned debt was credited to additional paid in capital.  This was done with the consent of all creditors.
	Settlement of debt at point of sale:		Amount
	Accounts payable	$	-54,389
	Royalty payable		-2,750
	Shareholder loan		-45,002
	Allowance for doubtful accounts		-9,000
	License fee receivable		15,000
	Paid in capital	$	96,141
	The convertible loan in the amount of $50,000 was also transferred and remains outstanding

PROMISSORY_NOTE_RELATED_PARTY

PROMISSORY NOTE - RELATED PARTY	9 Months Ended
	Sep. 30, 2014
PROMISSORY NOTE - RELATED PARTY	'
PROMISSORY NOTE - RELATED PARTY	'
	NOTE 5:  PROMISSORY NOTE - RELATED PARTY
	On August 8, 2014 the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (the owners of  CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually.
	The following table summarizes promissory note payable as of September 30, 2014:
			September 30,
			2014
	Promissory note payable, due on demand, interest at 7%	$	1,000,000
	Accrued interest		10,331
		$	1,010,331
	The Company recognized interest expense of $10,331 and $0 for the three and nine months ended September 30, 2014, respectively; and $0 and $0 for the three and nine months ended September 30, 2013, respectively

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2014
RELATED PARTY TRANSACTIONS:	'
RELATED PARTY TRANSACTIONS	'
	NOTE 6:  RELATED PARTY TRANSACTIONS
	From inception to September 30, 2014, the Company president advanced a total of $45,002 to fund working capital needs. That amount was settled as a part of the “Debt Settlement Agreement.”
	Effective November 26, 2012, the Company entered into a separate Convertible Loan Agreement with its President, under which it borrowed $50,000, and is due December 31, 2014, and does not bear interest.  The loan is convertible into common stock at $0.10 per share at the option of the lender any time after February 28, 2013.  As of September 30, 2014 the loan has not been converted.  The Company used the proceeds of this loan to fund the purchase of license rights under the November 26, 2012, agreement with Omega Research Corporation. The Convertible Loan was transferred to a third party.
	On May 21, 2014, the Company President advanced an additional $5,000 to the Company to fund working capital needs.  This brings the total amount due to shareholder to $55,000 as of September 30, 2014, including convertible loan.
	On August 8, 2014, the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (The owners of  CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually. For the three and nine months ended September 30, 2014 the Company charges $10,331 as interest expenses to operation (refer note 5).
	On June 25, 2014, the Company received a non interest bearing advance from CCB of $30,000 to pay the down payment on its D & O liability insurance.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2014
GOING CONCERN:	'
GOING CONCERN	'
	NOTE 7:  GOING CONCERN
	The Company’s unaudited condensed consolidated financial statements have been presented assuming that the Company will continue as a going concern.  As shown in the unaudited condensed consolidated financial statements, the Company has negative working capital of $188,909, has an accumulated deficit of $300,150, and presently does not have the resources to accomplish its objectives during the next twelve months. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

AMORTIZATION_AND_IMPAIRMENT

AMORTIZATION AND IMPAIRMENT	9 Months Ended
	Sep. 30, 2014
AMORTIZATION AND IMPAIRMENT	'
AMORTIZATION AND IMPAIRMENT	'
	NOTE 8: AMORTIZATION AND IMPAIRMENT
	The Company has determined that it is more likely than not that the value of the licenses has diminished. There is no open market for this type of asset and no comparable assets have recently traded. Therefore, the Company reduced the value of its intangible asset to nil. The Company during the three and nine months ended September 30, 2014, charged as impairment expenses of $0 and $52,103, respectively and for the three and nine months ended September 30, 2013 of $0 and $0, respectively, based on probable future cash flows.
	The Company during the three and nine months ended September 30, 2014 charged amortization expenses of $0 and $1,593, respectively and for the three and nine months ended September 30, 2013 of $2,500 and $7,500, respectively

DUE_TO_FIRST_INSURANCE_FUNDING

DUE TO FIRST INSURANCE FUNDING	9 Months Ended
	Sep. 30, 2014
DUE TO FIRST INSURANCE FUNDING	'
DUE TO FIRST INSURANCE FUNDING	'
	NOTE 9:  DUE TO FIRST INSURANCE FUNDING
	The Company financed the purchase of its D & O insurance with a note due to First Insurance Funding.  The principle amount financed was $120,000. Interest is due on the unpaid balance at a rate of 5.15 % per annum.  The total amount of interest due under the terms of the note is $3,116. The term of the note is nine months commencing August 25, 2014.  Payments are due for nine installments in the amount of $13,680, which includes principle and interest, commencing August 25, 2014.

COMMITMENT_AND_CONTINGENCIES

COMMITMENT AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
COMMITMENT AND CONTINGENCIES	'
COMMITMENT AND CONTINGENCIES	'
	NOTE 10:  COMMITMENT AND CONTINGENCIES
	On June 13, 2014, the Company entered into an employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary. The agreement’s effective date is June 1, 2014. The initial term of the agreement is one year.  The agreement renews each year until terminated by the Company or Dr. Anastassov. Cash remuneration is $20,000 per month payable bi-monthly. Following 12 months of continuous employment the agreement calls for a 500,000 share restricted stock grant of the Company’s common shares, or at the sole option of the Company, its cash equivalent based on the ten day average closing price of the company’s common stock immediately preceding the grant date, as quoted on Yahoo Finance.com. Following 15 months of continuous employment and every three months thereafter the agreement calls for a 125,000 share restricted stock grant of the Company’s common shares, or at the sole option of the Company, its cash equivalent based on the ten day average closing price of the company’s common stock immediately preceding the grant date, as quoted on Yahoo Finance.com

SUBSEQUENT_EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2014
SUBSEQUENT EVENT	'
SUBSEQUENT EVENT	'
	NOTE 11:  SUBSEQUENT EVENT
	Management evaluated all activities of the Company through the issuance date of the Company’s interim unaudited condensed consolidated financial statements and concluded that no subsequent events have occurred that would require adjustments or disclosure into the interim unaudited condensed consolidated financial statements

ACCOUNTING_POLICIES_POLICIES

ACCOUNTING POLICIES (POLICIES)	9 Months Ended
	Sep. 30, 2014
ACCOUNTING POLICIES (POLICIES):	'
Basis of presentation	'
	Basis of presentation
	The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").
Use of Estimates, Policy	'
	Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates
Cash Equivalents, Policy	'
	Cash equivalents
	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
Fair Value of Financial Instruments, Policy	'
	Fair value of financial instruments
	The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements
Income Taxes, Policy	'
	Income taxes
	The Company follows Section 740-10-30 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date.
	The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.
Net loss per common share	'
	Net loss per common share
	Net loss per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be antidilutive.
Recently issued accounting standards	'
	Recently issued accounting standards
	In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	The Company has elected to adopt the provisions of ASU 2014-10 for the current fiscal period ending September 30, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow.
	Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future unaudited condensed consolidated financial statements.

CHANGE_OF_CONTROL_TABLES

CHANGE OF CONTROL (TABLES)	9 Months Ended
	Sep. 30, 2014
CHANGE OF CONTROL (TABLES)	'
CHANGE OF CONTROL (TABLES)	'
	This was done with the consent of all creditors.
	Settlement of debt at point of sale:		Amount
	Accounts payable	$	-54,389
	Royalty payable		-2,750
	Shareholder loan		-45,002
	Allowance for doubtful accounts		-9,000
	License fee receivable		15,000
	Paid in capital	$	96,141

PROMISSORY_NOTE_RELATED_PARTY_

PROMISSORY NOTE - RELATED PARTY (TABLES)	9 Months Ended
	Sep. 30, 2014
PROMISSORY NOTE - RELATED PARTY (TABLES)	'
PROMISSORY NOTE - RELATED PARTY (TABLES)	'
	The following table summarizes promissory note payable as of September 30, 2014:
			September 30,
			2014
	Promissory note payable, due on demand, interest at 7%	$	1,000,000
	Accrued interest		10,331
		$	1,010,331

BASIS_OF_PRESENTATION_DETAILS

BASIS OF PRESENTATION (DETAILS) (USD $)	Jun. 09, 2014
BASIS OF PRESENTATION DETAILS	'
Number of authorized shares of common stock of the Company before increase	195,000,000
Number of authorized shares of common stock of the Company after increase	300,000,000
Common stock, per share value	$0.00

CHANGE_OF_CONTROL_Details

CHANGE OF CONTROL (Details) (USD $)	Mar. 21, 2014
Settlement of debt at point of sale:	'
Accounts payable	($54,389)
Royalty payable	-2,750
Shareholder loan	-45,002
Allowance for doubtful accounts	-9,000
License fee receivable	15,000
Paid in capital	96,141
Convertible loan transferred and outstanding	$50,000

Related_party_Promissory_note_

Related party Promissory note (Details) (USD $)	Sep. 30, 2014
Related party Promissory note	'
Promissory note payable, due on demand, interest at 7%	$1,000,000
Accrued interest on note	10,331
Total amount of note payable	$1,010,331

Interest_expense_Details

Interest expense (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Interest expense {1}	'	'	'	'
Company recognized interest expense	$10,331	$0	$0	$0

Related_party_agreements_Detai

Related party agreements (Details) (USD $)	Sep. 30, 2014	Aug. 08, 2014	Jun. 25, 2014	21-May-14
Related party agreements	'	'	'	'
Company president advanced to fund working capital needs	$45,002	'	'	$5,000
Total amount due to shareholder including convertible loan	55,000	'	'	'
Company entered into a separate Convertible Loan Agreement with its President and borrowed	50,000	'	'	'
The loan is convertible into common stock at a price per share	$0.10	'	'	'
Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC and borrowed to fund working capital	'	1,000,000	'	'
Interest expense charged by the company in the period	10,331	'	'	'
Company received a non interest bearing advance from CCB	'	'	$30,000	'

GOING_CONCERN_DETAILS

GOING CONCERN (DETAILS) (USD $)	Sep. 30, 2014
GOING CONCERN DETAILS	'
Company has negative working capital	$188,909
Incurred accumulated deficit in the period	$300,150

Impairment_expenses_of_Intangi

Impairment expenses of Intangible assets (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Impairment expenses of Intangible assets	'	'	'	'
Company charged as impairment expenses	$0	$0	$52,103	$0

First_Insurance_Funding_Detail

First Insurance Funding (Details) (USD $)	Sep. 30, 2014
First Insurance Funding	'
The principle amount financed	$120,000
Interest due on the unpaid balance at a rate per annum	5.15%
The total amount of interest due under the terms of the note	3,116
Payments are due for nine installments in the amount and includes principle and interest	$13,680

Employment_agreement_and_commi

Employment agreement and commitments (Details) (USD $)	Jun. 13, 2014
Employment agreement and commitments	'
Cash remuneration in the amount per month payable bi-monthly	$20,000
Restricted stock grant of the Company's common shares granted employment the agreement	500,000
Following 15 months of continuous employment and every three months thereafter the agreement Restricted stock granted	125,000